

Product Data Sheet

CD47 Protein, Human (HEK293, Fc)

Cat. No.:	HY-P7335
Synonyms:	rHuCD47, Fc Chimera; MER6; IAP; OA3
Species:	Human
Source:	HEK293
Accession:	Q08722 (Q19-P139)
Gene ID:	961
Molecular Weight:	Approximately 58.0 kDa.

PROPERTIES		
PROPERTIES		
AA Sequence	QLLFNKTKSV EFTFCNDTVV IPCFVTNMEA QNTTEVYVKW KFKGRDIYTF DGALNKSTVP TDFSSAKIEV SQLLKGDASL KMDKSDAVSH TGNYTCEVTE LTREGETIIE LKYRVVSWFS P	
Biological Activity	2 μg/mL (100 μL/well) of immoblized recombinant human SIRPa-His can bind human CD47-Fc with a linear range of 0.25-185 ng/mL.	
Appearance	Lyophilized powder.	
Formulation	Lyophilized after extensive dialysis against PBS.	
Endotoxin Level	<0.2 EU/µg, determined by LAL method.	
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).	
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.	
Shipping	Room temperature in continental US; may vary elsewhere.	

Background Targeting CD47 is in the spotlight of cancer immunotherapy. Blocking CD47 triggers the recognition and elimination of cancer cells by the innate immunity. The CD47/SIRP-α axis has been established as an important regulator of innate anti-cancer immunity, with many if not all malignancies overexpressing the receptor CD47 that binds to phagocyte-expressed SIRP-α^[1].

REFERENCES

[1]. Huang Y, et al. Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. J Thorac Dis. 2017 Feb;9(2):E168-E174.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA